Novartis AG — Investor Relations & Filings
Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth | 2018-10-18 | English | |
| PRIMARY DOCUMENT | 2018-10-04 | English | |
| PRIMARY DOCUMENT | 2018-09-14 | English | |
| FORM 6-K | 2018-09-06 | English | |
| FORM 6-K | 2018-08-29 | English | |
| FORM 6-K | 2018-08-23 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2018
15 filings
| |||||
| 4187507 | Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth | 2018-10-18 | English | ||
| 11301252 | PRIMARY DOCUMENT | 2018-10-04 | English | ||
| 11301253 | PRIMARY DOCUMENT | 2018-09-14 | English | ||
| 11301254 | FORM 6-K | 2018-09-06 | English | ||
| 11301255 | FORM 6-K | 2018-08-29 | English | ||
| 11301256 | FORM 6-K | 2018-08-23 | English | ||
| 4172053 | SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation | 2018-08-23 | English | ||
| 11301257 | PRIMARY DOCUMENT | 2018-08-22 | English | ||
| 11301258 | PRIMARY DOCUMENT | 2018-08-22 | English | ||
| 11301259 | PRIMARY DOCUMENT | 2018-08-20 | English | ||
| 11301263 | PRIMARY DOCUMENT | 2018-08-16 | English | ||
| 11301265 | PRIMARY DOCUMENT | 2018-08-14 | English | ||
| 11301267 | FORM 6-K | 2018-08-14 | English | ||
| 11301266 | PRIMARY DOCUMENT | 2018-08-10 | English | ||
| 11301268 | PRIMARY DOCUMENT | 2018-08-08 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Novartis AG, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Novartis AG via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/940/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=940 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=940 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=940 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 940}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Novartis AG (id: 940)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.